- In March 2022, Novartis had announced the approval of the European Commission (EC) Beovu (brolucizumab) 6 mg. it is used for treating visual impairment which occurs due to diabetic macular edema (DME). Year one data from the Phase III KESTREL and KITE studies, which compared Beovu (brolucizumab) 6 mg to aflibercept 2 mg in DME patients, were used to gain approval. Beovu was non-inferior to aflibercept in terms of change in best-corrected visual acuity (BCVA) from baseline in KESTREL and KITE, and showed promise for fluid resolution in numerically more DME patients than aflibercept
